Tagged With "Viaskin Peanut"

Blog Post

DBV to Resubmit Viaskin Peanut Treatment for FDA Biologics License

KFA News Team ·
Kids With Food Allergies is sharing this press release from DBV Technologies to bring you the latest research news quickly. [PRESS RELEASE] DBV Technologies Provides Update on Regulatory Status of Viaskin Peanut for the Treatment of PeanutAllergic Children 4 to 11 Years of Age Progress made to date to enable BLA resubmission in Q3 2019 Company to hold conference call today, February 13th, at 4:30 ET / 22:30 CET DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market:...
Comment

Re: DBV to Resubmit Viaskin Peanut Treatment for FDA Biologics License

Nutfreemama1 ·
Waiting for this! Already tried oit and slit.
Blog Post

FDA Application for Peanut Patch for Children 4 to 11 Years of Age Is Withdrawn

KFA News Team ·
DBV Technologies today announced that after discussions with the U.S. Food and Drug Administration (FDA), its Biologics License Application (BLA) for Viaskin Peanut in children four to 11 years of age has been voluntarily withdrawn. DBV is currently working closely with the agency to resubmit the application for Viaskin Peanut as quickly as possible.
Blog Post

FDA Gives Experimental Peanut Allergy Patch Special Status Designed to Speed Review

Kids With Food Allergies ·
The Food and Drug Administration agreed to review a skin patch for peanut allergy on an expedited basis following positive results of recent clinical trials, the company said Thursday.   DBV Technologies said that the FDA granted its Viaskin...
Blog Post

Food Allergy Research Update: Viaskin Study for Peanut Allergy

KFA News Team ·
Press Release: Consortium of Food Allergy Research Completes Recruitment of NIH-sponsored CoFar6 Phase II Trial with DBV's Viaskin(r) Peanut in Treatment of Peanut Allergy Leading US centers in food allergy involved in an NIH-funded CoFAR6 study,...
Blog Post

DBV Submits Viaskin Peanut Treatment for FDA Biologics License

KFA News Team ·
DBV Technologies today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for Viaskin Peanut for the treatment of peanut allergy in children four to 11 years of age. Viaskin Peanut is the Company’s lead product candidate, which is based on epicutaneous immunotherapy (EPIT), a proprietary technology platform that delivers biologically active compounds to the immune system
Comment

Re: FDA Gives Experimental Peanut Allergy Patch Special Status Designed to Speed Review

StephC ·
Same here. And how do we get notified about trials for milk?
Comment

Re: FDA Gives Experimental Peanut Allergy Patch Special Status Designed to Speed Review

Abigail's Mommy ·
How can we find a Phase III trial? I'm interested in doing this.
Kids With Food Allergies
A Division of the Asthma and Allergy Foundation of America
8201 Corporate Drive Suite 1000 Landover, MD 20785
Phone: 1-800-7-ASTHMA (1.800.727.8462)
-->
×
×
×
×